Hospital
Maniilaq Association
Maniilaq Association was paid $55.06M by Medicaid between Jan 2018 and Dec 2024, across 176 billing codes. Its largest line is C9803, Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source — 16% of everything it billed.
33Billing provider infoMANIILAQ ASSOCIATION
KOTZEBUE, AK 99752
KOTZEBUE, AK 99752
33aNPI1316995210assigned 05/04/2006
33bProvider typeCritical Access Hospital
28Total paid$55.06M
24GClaims283,127
24DCodes billed176
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Alaska
Rank by total paid#2 of 8
Median peer was paid$17.70M
This provider vs. median3.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 28,378 | $4.90M | |
| 2019 | 38,172 | $6.70M | |
| 2020 | 35,200 | $6.74M | |
| 2021 | 60,497 | $14.06M | |
| 2022 | 43,462 | $9.68M | |
| 2023 | 38,774 | $6.14M | |
| 2024incomplete | 38,644 | $6.84M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 16% | 16,648 | 13,144 | $8.78M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 11% | 15,037 | 11,895 | $5.99M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 9.3% | 18,985 | 14,987 | $5.15M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 7.6% | 21,748 | 14,710 | $4.17M |
| 80053 | Comprehensive metabolic panel | 6.7% | 11,372 | 9,137 | $3.70M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.1% | 14,339 | 8,463 | $2.27M |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 3.4% | 6,862 | 5,533 | $1.89M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.4% | 14,500 | 12,313 | $1.85M |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 3.3% | 4,279 | 3,427 | $1.81M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.9% | 4,244 | 3,543 | $1.60M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.2% | 1,890 | 1,010 | $1.22M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.9% | 4,059 | 3,643 | $1.03M |
164 more codes
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.7% | 1,985 | $940K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 3,416 | $919K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.6% | 2,235 | $854K |
| 92015 | Determination of refractive state | 1.5% | 2,378 | $807K |
| 85018 | 1.3% | 1,126 | $732K | |
| 81001 | 1.1% | 5,914 | $619K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 1.1% | 938 | $613K |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.0% | 5,912 | $564K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,676 | $490K |
| 86592 | <1% | 2,338 | $462K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,147 | $446K |
| 99284 | Emergency room visit (serious) | <1% | 8,744 | $392K |
| 87210 | <1% | 1,195 | $336K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 11,624 | $322K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,065 | $307K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,871 | $294K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 886 | $278K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,258 | $275K |
| 81025 | <1% | 2,160 | $260K | |
| 83540 | <1% | 377 | $252K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,472 | $246K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 595 | $245K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,336 | $223K |
| 86580 | <1% | 395 | $218K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 529 | $208K |
| 80306 | <1% | 2,104 | $188K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,379 | $187K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,570 | $186K |
| 85610 | <1% | 1,605 | $180K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 461 | $176K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 656 | $171K |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,584 | $167K |
| 80061 | Lipid panel | <1% | 2,289 | $162K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 416 | $142K |
| 87070 | <1% | 226 | $140K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,364 | $137K |
| 85027 | <1% | 2,781 | $130K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 311 | $118K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 3,405 | $117K |
| 84439 | <1% | 940 | $107K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 203 | $102K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,543 | $98K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 734 | $87K |
| 82962 | <1% | 178 | $86K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,597 | $72K |
| 82947 | <1% | 116 | $67K | |
| 81002 | <1% | 233 | $63K | |
| 86140 | <1% | 2,570 | $63K | |
| 84702 | <1% | 210 | $60K | |
| 92002 | <1% | 113 | $59K | |
| 81003 | <1% | 484 | $58K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 99 | $53K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 81 | $50K |
| 99443 | <1% | 107 | $50K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 269 | $46K |
| 90473 | <1% | 95 | $44K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 140 | $40K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,476 | $40K |
| 99442 | <1% | 86 | $39K | |
| 73130 | <1% | 123 | $39K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 946 | $35K |
| 76801 | <1% | 82 | $34K | |
| 99285 | Emergency room visit (most serious) | <1% | 4,386 | $33K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 682 | $31K |
| 92567 | <1% | 347 | $31K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 390 | $30K |
| 80076 | <1% | 190 | $30K | |
| 85008 | <1% | 726 | $28K | |
| 87081 | <1% | 102 | $27K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 131 | $24K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,284 | $23K |
| 82951 | <1% | 42 | $23K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 654 | $20K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 45 | $19K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 25 | $18K |
| 92504 | <1% | 48 | $18K | |
| 87807 | <1% | 232 | $18K | |
| 73610 | <1% | 46 | $17K | |
| 84484 | <1% | 1,320 | $16K | |
| 86900 | <1% | 663 | $14K | |
| 99441 | <1% | 33 | $14K | |
| 92557 | <1% | 29 | $14K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 219 | $13K |
| 87088 | <1% | 174 | $13K | |
| 83735 | <1% | 3,157 | $12K | |
| 71045 | Radiologic examination, chest; single view | <1% | 223 | $12K |
| 86803 | <1% | 1,284 | $11K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 155 | $11K |
| 92310 | <1% | 39 | $10K | |
| 83880 | <1% | 567 | $10K | |
| G0378 | Hospital observation service, per hour | <1% | 2,573 | $9K |
| 92555 | <1% | 59 | $9K | |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | <1% | 14 | $8K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 16 | $7K |
| 71250 | <1% | 13 | $7K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 55 | $7K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,733 | $7K |
| 73630 | <1% | 14 | $7K | |
| 82652 | <1% | 31 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 676 | $6K |
| 84703 | <1% | 153 | $6K | |
| 83690 | <1% | 2,034 | $6K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,977 | $5K |
| 86850 | <1% | 284 | $4K | |
| J2315 | Injection, naltrexone, depot form, 1 mg | <1% | 14 | $4K |
| 80047 | <1% | 21 | $4K | |
| 90686 | <1% | 23 | $4K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 32 | $4K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 16 | $4K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 220 | $4K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 205 | $4K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 26 | $4K |
| 73030 | <1% | 12 | $3K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 16 | $3K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 91 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 204 | $3K |
| 87340 | <1% | 297 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,141 | $3K |
| 73100 | <1% | 16 | $2K | |
| 82043 | <1% | 18 | $2K | |
| 82607 | <1% | 60 | $2K | |
| 70486 | <1% | 18 | $2K | |
| 90474 | <1% | 215 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 14 | $2K |
| 82570 | <1% | 29 | $2K | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 110 | $2K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 17 | $2K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 139 | $2K |
| 36416 | <1% | 49 | $1K | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 32 | $1K |
| 81015 | <1% | 22 | $1K | |
| 83605 | <1% | 308 | $1K | |
| 85730 | <1% | 225 | $710.00 | |
| 87040 | <1% | 58 | $653.00 | |
| 87206 | <1% | 77 | $653.00 | |
| 97161 | <1% | 54 | $116.00 | |
| 80320 | 0% | 2,356 | $0.00 | |
| Q3014 | Telehealth originating site facility fee | 0% | 129 | $0.00 |
| 80329 | 0% | 133 | $0.00 | |
| 85651 | 0% | 173 | $0.00 | |
| 82553 | 0% | 14 | $0.00 | |
| 86762 | 0% | 157 | $0.00 | |
| 82550 | 0% | 30 | $0.00 | |
| 83874 | 0% | 14 | $0.00 | |
| 99217 | 0% | 293 | $0.00 | |
| 96368 | 0% | 13 | $0.00 | |
| 82150 | 0% | 17 | $0.00 | |
| 99232 | Hospital visit by a doctor, follow-up day | 0% | 51 | $0.00 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 0% | 42 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 20 | $0.00 |
| 96127 | 0% | 15 | $0.00 | |
| 99220 | 0% | 28 | $0.00 | |
| 90480 | 0% | 18 | $0.00 | |
| 96376 | 0% | 53 | $0.00 | |
| 92587 | 0% | 19 | $0.00 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 0% | 204 | $0.00 |
| 84100 | 0% | 111 | $0.00 | |
| 99238 | Hospital discharge day management, 30 minutes or less | 0% | 282 | $0.00 |
| 84481 | 0% | 17 | $0.00 | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | 0% | 104 | $0.00 |
| 99218 | 0% | 55 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 31 | $0.00 |
| J0570 | Buprenorphine implant, 74.2 mg | 0% | 13 | $0.00 |
| 90832 | Psychotherapy session, about 30 minutes | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHANSEN, PAUL (DEPUTY ADMINISTRATOR)
Parent organizationMANIILAQ ASSOCIATION
| Provider | Location | Paid |
|---|---|---|
| Maniilaq Association | Kotzebue, AK | $2.25M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.